July 28, 2026 · Decision research
Biotech Pharma Breakthroughs
Finding
The prior sweep's headline claim that GLP-1 second-order demand destruction in food/beverage and healthcare is "underpriced" is half-right and half-wrong. The 2026 data validates the directional story (bariatric surgery volumes down 23% from peak, General Mills cutting guidance) but contradicts the magnitude (restaurants are GAINING visits from GLP-1 users, and 90-95% of the eligible obese population remains untreated, capping absolute impact). The single weakest assumption was persistence, not size.
What changed
Three pieces of 2026 evidence materially stress-test the prior thesis. (1) The National Restaurant Association's May 2026 consumer study shows GLP-1 users eat out 7.6 times/week versus 5.1 for non-users, with 76% willing to pay a premium for aligned menus - the opposite of the "restaurants die" narrative. (2) Bariatric surgery fell from a 2022 peak of 230,707 to 177,789 in 2024 (-23%), confirming substitution but at a small absolute base (0.21% of severely obese patients get surgery). (3) GLP-1 one-year persistence sits at only 32%, with 42% dropping out by 9 months - meaning the demand-destruction cohort is largely transient, blunting the structural case. Walmart, Conagra, and Kroger are pivoting toward GLP-1 users, not away from them.
Decision
HOLD with the position reframed. The pharma upside remains intact (Lilly's orforglipron approval plus $25 pricing, CMS Medicare bridge at $50/month starting July 1, 2026, oral GLP-1 from Novo expected). The "demand destruction in CPG/restaurants" trade is partially right for snacks, frozen meals, and sugary drinks, but wrong as a broad brush - food companies are monetizing the GLP-1 user, not being destroyed by them. Net: do not fade Lilly/Novo on a macro-food thesis; do fade indiscriminate CPG-bear trades. Action stays "consider," but the second-order leg is structurally smaller than consensus assumed. The bigger, more durable trade remains the pharma TAM expansion at the manufacturer level.
Watch next
(a) Q3-Q4 2026 CPG earnings calls for quantified volume erosion language from General Mills, Conagra, Hershey, or Kraft Heinz; (b) CMS GLP-1 bridge enrollment numbers (any print above 500K beneficiaries in the first 90 days reshapes the TAM curve); (c) Novo's oral GLP-1 approval and pricing response to orforglipron; (d) 12-month real-world persistence data from claims databases (Optum, Truven, CMS Bridge first-year cohort); (e) restaurant Q2 same-store-sales prints versus NRA baseline, particularly for chains with high midday/snack dayparts.